Skip to main content
Caplight Logo









Newrotex

Newrotex

Private
OxfordHealthcare & Life Scienceshttps://newrotex.com/

Last Round

Grant

Jan 1, 2024

Total Funding Raised

$6.03M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Newrotex is a surgical devices company that develops silk-based medical solutions for peripheral nerve repair.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

peripheral nerve repairnerve regenerationnerve conduitautograft alternativesilk-based medical deviceregenerative medicinelarge-gap nerve injurytissue engineeringnerve guidance conduitspider silk implantbiomaterialsclinical-stage biotechreconstructive surgerymedical device manufacturingISO 13485

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Newrotex Comparables

Compare Newrotex with similar companies based on industry and business-model similarity.

Newrotex comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ReNerve Limited
83%
Axonova Medical
81%
Auxilium Biotechnologies
78%

Newrotex Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJan 1, 2024
AcceleratorOct 11, 2023
GrantMar 22, 2023
GrantAug 1, 2022
GrantMay 1, 2020
Grant
May 1, 2020

Key People

Founding team and executive leadership

Alex Woods

Co-Founder & CEO

Founding Team

Katie Slater

Chief Operating Officer

Executive Team

Newrotex Investors

Notable investors and investment history

Newrotex investors
InvestorRounds
European Innovation Council FundGrant
Horizon Europe GuaranteeGrant
MedTech InnovatorAccelerator
Innovate UKGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 100% MoM, reaching 3.1K.

  • Apr 17, 2026

    Monthly visitors grew 210% MoM, reaching 1.7K.

Newrotex Filings

Explore SEC and related filing metadata, where available.

Newrotex filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Newrotex's valuation, stock price, and market status.

Is Newrotex a public or private company?

Newrotex is a private company.

What is the current stock price of Newrotex?

Newrotex is a private company with no public stock price. No recent secondary market data is available.

How much is Newrotex worth (valuation)?

Valuation information for Newrotex is not publicly available.

Can I buy Newrotex stock?

Newrotex shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Newrotex's last funding round?

Newrotex's most recent funding round was Grant on January 1, 2024.

Who are the main investors in Newrotex?

Key investors in Newrotex include European Innovation Council, Horizon Europe Guarantee, Innovate UK.

Will Newrotex IPO soon?

No public IPO plans have been announced for Newrotex.

How can I track Newrotex secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Newrotex's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersOxford
Employee Range6
Year Founded2019
Last FundingJan 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?